Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

por de la Fuente, Macarena I, Colman, Howard, Rosenthal, Mark, Van Tine, Brian A, Levacic, Danijela, Walbert, Tobias, Gan, Hui K, Vieito, Maria, Milhem, Mohammed M, Lipford, Kathryn, Forsyth, Sanjeev, Guichard, Sylvie M, Mikhailov, Yelena, Sedkov, Alexander, Brevard, Julie, Kelly, Patrick F, Mohamed, Hesham, Monga, Varun
Publicado 2022